DLA Piper represented Plexium, a San Diego-based emerging biotechnology company whose proprietary platform, DELPhe, enables cell-based phenotypic screening of DNA-encoded libraries in nanoliter volumes, in its US$28 million Series A financing.

Proceeds from the financing, which was led by DCVC Bio and The Column Group, with participation from M Ventures, CRV and Neotribe Ventures, will be used to advance DELPhe and use DELPhe to build a pipeline of small molecules that modulate E3 ligases to selectively enhance and degrade protein targets.

The DLA Piper team representing Plexium was led by partner Michael Brown and included associates Shehzad Huda and Anthony Taranto (all of San Diego).